Recent Updates
Recently added Catalysts
INKT Positive Sentiment Score: 70/100

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Monday, October 30, 2023 1 min read
Key Takeaway: MiNK Therapeutics, Inc. (NASDAQ: INKT) has announced the upcoming release of its third quarter 2023 financial results, scheduled for November 9, 2023. As a clinical-stage biopharmaceutical company, MiNK is focused on developing allogeneic iNKT cell therapies for cancer and other immune-mediated diseases. The company's work emphasizes scalable and reproducible manufacturing, positioning it as a key player in therapeutic innovation within its sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • MiNK Therapeutics is on track to release its financial results, indicating transparency and communication with investors.
  • The focus on innovative iNKT cell therapies positions the company at the forefront of cancer treatment advancements.
  • The structured pipeline of both native and engineered iNKT programs demonstrates potential for significant therapeutic impact.

Full Press Release Details

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its third quarter 2023 financial results via press release before the market opens on Thursday, Nov. 9, 2023.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/ or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels.
investor@minktherapeutics.com
communications@minktherapeutics.com

Frequently Asked Questions

When will MiNK Therapeutics release Q3 2023 financial results?

MiNK Therapeutics will release its Q3 2023 financial results on November 9, 2023.

What type of therapies does MiNK Therapeutics develop?

MiNK Therapeutics develops allogeneic invariant natural killer T (iNKT) cell therapies.

Where is MiNK Therapeutics located?

MiNK Therapeutics is headquartered in New York, NY.

What is the focus of MiNK Therapeutics?

The company focuses on treating cancer and immune-mediated diseases.

Tags: INKT Viatris Investor Conferences Healthcare MiNK Therapeutics iNKT therapies cancer treatment biopharmaceutical NASDAQ: INKT
Last updated: Oct 30, 2023